Our top pick for
HUTCHMED (China) Limited is a biotechnology business based in the US. HUTCHMED China shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. HUTCHMED China employs 1,280 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$32.06|
|52-week range||$23.67 - $43.94|
|50-day moving average||$35.55|
|200-day moving average||$34.16|
|Wall St. target price||$46.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.24|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-0.62%|
|1 month (2021-09-27)||-14.05%|
|3 months (2021-07-27)||-12.04%|
|6 months (2021-04-27)||6.90%|
|1 year (2020-10-26)||6.69%|
|2 years (2019-10-25)||59.82%|
|3 years (2018-10-26)||8.27%|
|5 years (2016-10-26)||172.62%|
|Revenue TTM||$278.6 million|
|Gross profit TTM||$-135,319,000|
|Return on assets TTM||-18.23%|
|Return on equity TTM||-24.13%|
|Market capitalisation||$5.7 billion|
TTM: trailing 12 months
There are currently 1.8 million HUTCHMED China shares held short by investors – that's known as HUTCHMED China's "short interest". This figure is 3.6% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting HUTCHMED China shares can be evaluated.
HUTCHMED China's "short interest ratio" (SIR) is the quantity of HUTCHMED China shares currently shorted divided by the average quantity of HUTCHMED China shares traded daily (recently around 195286.66666667). HUTCHMED China's SIR currently stands at 9. In other words for every 100,000 HUTCHMED China shares traded daily on the market, roughly 9000 shares are currently held short.
However HUTCHMED China's short interest can also be evaluated against the total number of HUTCHMED China shares, or, against the total number of tradable HUTCHMED China shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HUTCHMED China's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 HUTCHMED China shares in existence, roughly 10 shares are currently held short) or 0.019% of the tradable shares (for every 100,000 tradable HUTCHMED China shares, roughly 19 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against HUTCHMED China.
Find out more about how you can short HUTCHMED China stock.
We're not expecting HUTCHMED China to pay a dividend over the next 12 months.
HUTCHMED China's shares were split on a 10:1 basis on 29 May 2019. So if you had owned 1 share the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your HUTCHMED China shares – just the quantity. However, indirectly, the new 90% lower share price could have impacted the market appetite for HUTCHMED China shares which in turn could have impacted HUTCHMED China's share price.
Over the last 12 months, HUTCHMED China's shares have ranged in value from as little as $23.67 up to $43.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HUTCHMED China's is 0.6657. This would suggest that HUTCHMED China's shares are less volatile than average (for this exchange).
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.